Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

PROCESSA PHARMACEUTICALS INC (PCSA)

10 + Investors. Track Smart Money conviction in PCSA. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
50%

Smart Money Signals — PCSA

Based on 10 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
📊

High ownership — 77% of 3.0Y peak

77% of all-time peak
10 funds currently hold this stock — 77% of the 3.0-year high of 13 funds (reached 2025 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +11% more funds vs a year ago

fund count last 6Q
+1 new funds entered over the past year (+11% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 50% buying

6 buying6 selling
Last quarter: 6 funds bought or added vs 6 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~4 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 5 → 7 → 3 → 4. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 30% long-term, 50% new

30% conviction (2yr+) 20% medium 50% new
Of the 10 current holders: 3 (30%) held >2 years, 2 held 1–2 years, and 5 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares +54%, value +35%

Value
+35%
Shares
+54%
Last quarter: funds added +54% more shares while total portfolio value only changed +35%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
⚠️

Saturation — most institutions already know this story

2 → 5 → 7 → 3 → 4 new funds/Q
New funds entering each quarter: 5 → 7 → 3 → 4. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.
📊

Mixed cohorts — 20% veterans, 50% new entrants

20% veterans 30% 1-2yr 50% new
Of 10 current holders: 2 (20%) held 2+ years, 3 held 1–2 years, 5 (50%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 15% AUM from top-100

15% from top-100 AUM funds
5 of 10 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.1
out of 10
Low Exit Risk
Exit risk score 3.1/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PCSA

In 2026 Q1, 6 hedge funds were net buyers of PCSA (4 opened a new position, 2 added to an existing one), while 6 reduced or exited (2 trimmed, 4 sold completely) — a 50% buyer ratio, indicating a slight buying edge. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 10.

Hedge Fund Ownership: PCSA

How many hedge funds hold PCSA — quarterly history vs. share price
Quarterly hedge fund ownership of PCSA vs. share price

Market Analysis: PCSA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PCSA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy PROCESSA PHARMACEUTICALS INC (PCSA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PCSA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 68d ago
PCSA
-0.1%
XLV
+0.0%

PCSA outperformed XLV by -0.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 23d ago
PCSA
-14.9%
XLV
+0.0%

Since the filing became public, PCSA outperformed XLV by -14.9% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 0 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: PCSA
10 + Investors

Track Smart Money conviction in PCSA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 10 10 -
13F Shares 178K 115K 54.29%
Total Value $448K $331K 35.49%
New Positions 4 3 +1
Increased Positions 2 0 +2
Closed Positions 4 6 -2
Reduced Positions 2 7 -5
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: PCSA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

10 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PCSA. Verified SEC 13F-HR filings.

QUARTER:
Top 9 institutional holders of PCSA — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Connective Capital Management, LLC 0.15% 70,736 $179K
2 Stonepine Capital Management, LLC 0.06% 55,000 $139K
3 Tower Research Capital LLC (TRC) 0.00% 918 $2K
4 VANGUARD FIDUCIARY TRUST CO 0.00% 10,857 $27K
5 UBS Group AG 0.00% 2,531 $6K
6 VANGUARD CAPITAL MANAGEMENT LLC 0.00% 12,729 $32K
7 CITIGROUP INC 0.00% 14
8 JONES FINANCIAL COMPANIES LLLP 0.00% 7
9 WELLS FARGO & COMPANY/MN 0.00% 6
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — PROCESSA PHARMACEUTICALS INC (PCSA)

What does the Smart Money Trend signal show for PCSA?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for PCSA?

Slight buying edge — 50% buying: Last quarter: 6 funds bought or added vs 6 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PCSA holders?

Smaller funds dominant — 15% AUM from top-100: 5 of 10 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held PCSA?

Mixed — 30% long-term, 50% new: Of the 10 current holders: 3 (30%) held >2 years, 2 held 1–2 years, and 5 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy PROCESSA PHARMACEUTICALS INC (PCSA) following the 2026 Q1 hedge fund 13F filings?

As of today, PCSA has moved -14.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of -14.9%. Since the quarter end (March 31, 2026), PCSA has gained -0.1% vs +0.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →